Trial Profile
A phase 1 multiple ascending dose (MAD) clinical trial of SNDX-6352 (UCB-6352) in patients with solid tumours
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Mar 2018
Price :
$35
*
At a glance
- Drugs Axatilimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 09 Mar 2018 New trial record
- 05 Mar 2018 According to a Syndax Pharmaceuticals media release, the company anticipated presenting data from this trial in the second half of 2018.